{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:02:57Z","timestamp":1789588977662,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["221590\/Z\/20\/Z"],"award-info":[{"award-number":["221590\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V028391\/1"],"award-info":[{"award-number":["MR\/V028391\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jpba.2023.115436","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T16:08:43Z","timestamp":1683043723000},"page":"115436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Development and validation of an LC-MS\/MS method for quantification of favipiravir in human plasma"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-6067","authenticated-orcid":false,"given":"Elizabeth","family":"Challenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujan Dilly","family":"Penchala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Chiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Else","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpba.2023.115436_bib1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jpba.2023.115436_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.jpba.2023.115436_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.jpba.2023.115436_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2023.115436_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104955","article-title":"Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes","volume":"184","author":"Choi","year":"2020","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.jpba.2023.115436_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01833-20","article-title":"GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection","volume":"11","author":"Hattori","year":"2020","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.jpba.2023.115436_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.jpba.2023.115436_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101703","article-title":"Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial","volume":"54","author":"McMahon","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.jpba.2023.115436_bib9","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cmi.2021.12.026","article-title":"Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial","volume":"28","author":"Bosaeed","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"10.1016\/j.jpba.2023.115436_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab962","article-title":"Favipiravir study, efficacy of early treatment with favipiravir on disease progression among high-risk patients with coronavirus disease 2019 (COVID-19): a randomized, open-label clinical trial","volume":"75","author":"Chuah","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.jpba.2023.115436_bib11","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/cid\/ciac312","article-title":"Favipiravir for treatment of outpatients with asymptomatic or uncomplicated coronavirus disease 2019: a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Holubar","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.jpba.2023.115436_bib12","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkab135","article-title":"Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2","volume":"76","author":"Pertinez","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.jpba.2023.115436_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep."},{"key":"10.1016\/j.jpba.2023.115436_bib14","first-page":"1","article-title":"The outcomes of favipiravir exposure in pregnancy: a case series","author":"Ertem","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.jpba.2023.115436_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejogrb.2021.12.001","article-title":"Favipiravir exposure and pregnancy outcome of COVID-19 patients","volume":"268","author":"Tirmikcioglu","year":"2022","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jpba.2023.115436_bib16","article-title":"Development of a highly sensitive bioanalytical assay for the quantification of favipiravir","author":"Curley","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.jpba.2023.115436_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114057","article-title":"A novel LC-MS\/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers","volume":"199","author":"Morsy","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.jpba.2023.115436_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5098","article-title":"A novel, rapid and simple UPLC-MS\/MS method for quantification of favipiravir in human plasma: Application to a bioequivalence study","volume":"35","author":"Rezk","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2023.115436_bib19","unstructured":"E.M. Agency, Guideline on bioanalytical method validation. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf\u3009, 2012 (accessed 08 December.2022)."},{"key":"10.1016\/j.jpba.2023.115436_bib20","unstructured":"U.S.D.o.H.a.H.S.F.a.D. Administration, Bioanalytical Method Validation Guidance for Industry. \u3008https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf\u3009, 2018 (accessed 8 December.2022)."},{"issue":"13","key":"10.1016\/j.jpba.2023.115436_bib21","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2023.115436_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122768","article-title":"Development and validation of a sensitive, fast and simple LC-MS \/ MS method for the quantitation of favipiravir in human serum","volume":"1176","author":"Eryavuz Onmaz","year":"2021","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.jpba.2023.115436_bib23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jpba.2006.08.010","article-title":"Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC\/MS\/MS method for the determination of carvedilol enantiomers in human plasma","volume":"43","author":"Wang","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115436_bib24","unstructured":"H.a.S.E.A.C.o.D. Pathogens, The approved list of biological agents. \u3008https:\/\/www.hse.gov.uk\/pubns\/misc208.pdf\u3009, 2021 (accessed 02 March.2023)."},{"key":"10.1016\/j.jpba.2023.115436_bib25","article-title":"Effective heat inactivation of SARS-CoV-2","author":"Wang","year":"2020","journal-title":"medRxiv"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523002054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523002054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:27:15Z","timestamp":1760002035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523002054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":25,"alternative-id":["S0731708523002054"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115436","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an LC-MS\/MS method for quantification of favipiravir in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115436"}}